Phenotype
|
Fish
|
Conditions
|
Figures
|
intermediate cell mass of mesoderm drll.3 expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm drl expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
erythroid lineage cell slc4a1a expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
hematopoietic system drll.3 expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm drll.2 expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
blood island spi1b expression mislocalised, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 2
from Takeuchi et al., 2015
|
intermediate cell mass of mesoderm drll.1 expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
hematopoietic system drll.2 expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm spi1b expression mislocalised, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
intermediate cell mass of mesoderm spi1b expression increased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm slc4a1a expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
hematopoietic system drl expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
hematopoietic system drll.1 expression decreased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
monocyte lcp1 expression increased amount, abnormal
|
AB + MO1-gata1a
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
caudal hematopoietic tissue blvra expression increased amount, abnormal
|
TL + MO1-gata1a
|
standard conditions
|
Fig. 6
from Holowiecki et al., 2017
|
liver blvrb expression increased amount, abnormal
|
TL + MO1-gata1a
|
standard conditions
|
Fig. 6
from Holowiecki et al., 2017
|
intermediate cell mass of mesoderm blvra expression decreased amount, abnormal
|
TL + MO1-gata1a
|
standard conditions
|
Fig. 6
from Holowiecki et al., 2017
|
intermediate cell mass of mesoderm blvrb expression absent, abnormal
|
TL + MO1-gata1a
|
standard conditions
|
Fig. 6
from Holowiecki et al., 2017
|
caudal hematopoietic tissue blvrb expression increased amount, abnormal
|
TL + MO1-gata1a
|
standard conditions
|
Fig. 6
from Holowiecki et al., 2017
|
heart blvrb expression increased amount, abnormal
|
TL + MO1-gata1a
|
standard conditions
|
Fig. 6
from Holowiecki et al., 2017
|
nucleate erythrocyte hbae1.1 expression increased distribution, abnormal
|
TU + MO1-gata1a
|
control
|
Fig. 5
from Li et al., 2020
|
blood circulating cell absent, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. 2
from Vermot et al., 2009
|
atrioventricular valve morphology, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. 2
from Vermot et al., 2009
|
whole organism foxc1b expression decreased amount, abnormal
|
WT + MO1-gata1a
|
control
|
Fig. 6
from Chen et al., 2017
|
nucleate erythrocyte development disrupted, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. 8
from Helker et al., 2013
|
nucleate erythrocyte absent, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. 8
from Helker et al., 2013
|
common cardinal vein blood vessel endothelial cell decreased amount, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. 8
from Helker et al., 2013
|
myeloid cell increased amount, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. S6
from Hall et al., 2007
|
blood decreased viscosity, abnormal
|
WT + MO1-gata1a
|
standard conditions
|
Fig. 2
from Vermot et al., 2009
|
whole organism foxc1a expression decreased amount, abnormal
|
WT + MO1-gata1a
|
control
|
Fig. 6
from Chen et al., 2017
|
dorsal aorta foxc1b expression decreased amount, abnormal
|
hu10049Tg + MO1-gata1a
|
control
|
Fig. 6
from Chen et al., 2017
|
whole organism foxc1b expression decreased amount, abnormal
|
hu10049Tg + MO1-gata1a
|
control
|
Fig. 6
from Chen et al., 2017
|
cardiac ventricle EGFP expression increased amount, abnormal
|
ig11Tg + MO1-gata1a
|
control
|
Fig. 2
from Heckel et al., 2015
|
endothelial cell jag1b expression decreased amount, abnormal
|
s843Tg + MO1-gata1a
|
control
|
Fig. 4
from Chen et al., 2017
|
endothelial cell hey1 expression decreased amount, abnormal
|
s843Tg + MO1-gata1a
|
control
|
Fig. 4
from Chen et al., 2017
|
endothelial cell hey2 expression decreased amount, abnormal
|
s843Tg + MO1-gata1a
|
control
|
Fig. 4
from Chen et al., 2017
|
endothelial cell notch1b expression decreased amount, abnormal
|
s843Tg + MO1-gata1a
|
control
|
Fig. 4
from Chen et al., 2017
|
endothelial cell her9 expression decreased amount, abnormal
|
s843Tg + MO1-gata1a
|
control
|
Fig. 4
from Chen et al., 2017
|
atrioventricular canal blood circulation process quality, abnormal
|
sd2Tg + MO1-gata1a
|
control
|
Fig. 2
from Heckel et al., 2015
|
atrioventricular canal ab2-fn labeling increased amount, abnormal
|
ubs10Tg + MO1-gata1a
|
control
|
Fig. 5
from Steed et al., 2016
|
atrial endocardium endothelial cell increased amount, abnormal
|
ubs10Tg + MO1-gata1a
|
control
|
Fig. 2
from Heckel et al., 2015
|
dorsal aorta vascular associated smooth muscle cell mCherry expression absent, abnormal
|
s843Tg; uto5Tg + MO1-gata1a
|
control
|
Fig. 2
from Chen et al., 2017
|
nucleate erythrocyte absent, abnormal
|
s843Tg; uto5Tg + MO1-gata1a
|
control
|
Fig. 2
from Chen et al., 2017
|
dorsal aorta vascular associated smooth muscle cell decreased amount, abnormal
|
s843Tg; uto5Tg + MO1-gata1a
|
control
|
Fig. 2
from Chen et al., 2017
|
dorsal aorta anatomical region mCherry expression absent, abnormal
|
s843Tg; uto5Tg + MO1-gata1a
|
control
|
Fig. 2
from Chen et al., 2017
|
intermediate cell mass of mesoderm spi1b expression position, ameliorated
|
kdm1ait627/it627 + MO1-gata1a (AB)
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
blood island spi1b expression position, ameliorated
|
kdm1ait627/it627 + MO1-gata1a (AB)
|
standard conditions
|
Fig. 2
from Takeuchi et al., 2015
|
nucleate erythrocyte hbae1.1 expression spatial pattern, ameliorated
|
p2ry12sih3/sih3 + MO1-gata1a (TU)
|
control
|
Fig. 5
from Li et al., 2020
|
intermediate cell mass of mesoderm spi1b expression mislocalised, abnormal
|
AB + MO1-etsrp + MO1-gata1a
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
blood decreased viscosity, abnormal
|
WT + MO1-gata1a + MO1-gata2a
|
standard conditions
|
Fig. 2
from Vermot et al., 2009
|
blood circulating cell absent, abnormal
|
WT + MO1-gata1a + MO1-gata2a
|
standard conditions
|
Fig. 2
from Vermot et al., 2009
|
atrioventricular valve morphology, abnormal
|
WT + MO1-gata1a + MO1-gata2a
|
standard conditions
|
Fig. 2
from Vermot et al., 2009
|
intermediate cell mass of mesoderm spi1b expression position, ameliorated
|
kdm1ait627/it627 + MO1-etsrp + MO1-gata1a (AB)
|
standard conditions
|
Fig. 4
from Takeuchi et al., 2015
|
atrioventricular canal EGFP expression decreased amount, abnormal
|
ig11Tg + MO1-gata1a + MO1-gata2a
|
control
|
Fig. 2
from Heckel et al., 2015
|
caudal vein plexus size, ameliorated
|
y1Tg + CRISPR1-ccm2 + CRISPR2-ccm2 + CRISPR3-ccm2 + CRISPR4-ccm2 + MO1-gata1a
|
standard conditions
|
Figure 4
from Li et al., 2021
|
dorsal aorta foxc1b expression amount, ameliorated
|
hu10049Tg; kca3Tg + MO1-gata1a
|
control
|
Fig. 6
from Chen et al., 2017
|
whole organism foxc1b expression amount, ameliorated
|
hu10049Tg; kca3Tg + MO1-gata1a
|
control
|
Fig. 6
from Chen et al., 2017
|